Brought to you by 
Novavax nets $36.1mm with private placement
04 May 2006
Executive Summary
Novavax (vaccines and drug delivery technologies), which raised $20mm through a private financing last month, has now netted $36.1mm from a private placement of 5.2mm common shares at $7.30 each (a 12% premium). Rodman & Renshaw acted as placement agent for the transaction. This month Novavax also signed a deal with Bharat Biotech International to develop a vaccine for the avian flu.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Liposomes
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novavax nets $36.1mm with private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice